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BACKGROUND: Barrett's esophagus metaplasia is the key precursor lesion of esophageal adenocarcinoma. The
aim of this study was to find a subset of markers that may allow the identification of patients at risk for esophageal
adenocarcinoma, and to determine genes differentially expressed in esophageal squamous cell carcinoma.
METHODS: Laser capture microdissection technique was applied to procure cells from defined regions. Genome-
wide RNA profiling was performed on esophageal adenocarcinoma (n = 21), Barrett's esophagus (n = 20),
esophageal squamous carcinoma (n = 9) and healthy esophageal biopsies (n = 18) using the Affymetrix Human
Genome U133plus 2.0 array. Microarray results were validated by quantitative real-time polymerase chain reaction
in a second and independent cohort and by immunohistochemistry of two putative markers in a third independent
cohort. RESULTS: Through unsupervised hierarchical clustering and principal component analysis, samples were
separated into four distinct groups that match perfectly with histology. Many genes down-regulated in esophageal
cancers belong to the epidermal differentiation complex or the related GO-group “cornified envelope” of terminally
differentiated keratinocytes. Similarly, retinol metabolism was strongly down-regulated. Genes showing strong
overexpression in esophageal carcinomas belong to the GO groups extracellular region /matrix such as MMP1,
CTHRC1, and INHBA. According to an analysis of genes strongly up-regulated in both esophageal adenocarcinoma
and Barrett's esophagus, REG4 might be of particular interest as an early marker for esophageal adenocarcinoma.
CONCLUSIONS: Our study provides high quality data, which could serve for identification of potential biomarkers
of Barrett's esophagus at risk of esophageal adenocarcinoma progression.
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Barrett's esophagus, a condition in which a metaplastic columnar
mucosa that confers a predisposition to cancer replaces an esophageal
squamous mucosa, is a major risk factor for esophageal adenocarci-
noma (EAC). The frequency of this deadly tumor has increased
significantly during the past four decades [1]. Barrett's esophagus
(BE) is associated with a 40-fold increased risk for the development of
EAC, which gradually progresses to carcinoma through a metaplasia–
dysplasia–carcinoma sequence [2]. Thus, a better understanding of
the pathogenesis of Barrett's associated cancer is required for risk
prediction and the development of effective therapeutic strategies.
Esophageal squamous cell carcinoma (ESCC) is another histological
subtype which is detected mostly at advanced stages leading to a low
survival of the patients [3].
In many types of carcinomas, biomarkers can enhance our ability
for diagnosis, prognosis, and for therapy prediction. At present there
are no clinical or histological parameters that allow the identification
of patients bearing a high risk of progression of BE to EAC. One of
the reasons might be that esophageal Barrett's adenocarcinomas are
quite heterogeneous. A number of possible markers have been
identified, e.g. aneuploidy [4], copy number alterations [5] and
deletion of the p16 tumor suppressor gene [6]. Similarly, miRNAs
might be potential biomarkers [7]. EGFR was found to be
overexpressed in high-grade dysplasia and adenocarcinoma of the
esophagus [8]. However, none of the currently known molecular
biomarkers has sufficient predictive power to identify BE progression
in a clinically useful manner [9].
Gene expression profiling by microarrays is a powerful technique
for delineating biomarkers and pathways associated with cancer
progression [10]. Here, also laser capture microdissection (LMD) was
applied to collect cells from defined regions of histologic tissue. We
focused on neoplastic progression and found a set of genes
representing potential biomarkers which might help to create a
more standardized, reproducible and reliable diagnostic procedure in
order to stratify patients with BE in terms of their risk to develop
cancer. Expression of these genes can be determined in a quantitative
way, and thus may be able to complement conventional
semi-quantitative histological analysis.
Materials and Methods
Patients and Tissue Specimens
Unselected patients seeking treatment for Barrett's esophagus or
esophageal cancer at Charité-Universitätsmedizin (Berlin, Germany)
were enrolled in the study. Gene expression profiling using
whole-human-genome microarrays (Affymetrix U133plus2) was per-
formed on 21 EAC, 20 BE, 9 ESCC and 18NE biopsies (biopsies from
patients without esophageal pathology), collected from 68 individuals.
Patients' age ranged from 22 to 79 years, with a median age of 58 years.
The validation cohort for RT-PCR verification consisted of 49
esophageal specimens, including 10 EAC, 7 ESCC, 20 BE and 12
NE. Patients' age ranged from 24 to 79 years, with a median age of 59
years. NE biopsies were collected from patients with esophageal pain
but diagnosed as normal squamous without pathological changes. BE
biopsies were taken during upper gastrointestinal endoscopy with
biopsy sampling from year 2005 to 2010. Surgical specimens of
chemotherapy-naive patients with known EAC of histological grading
G1, UICC stage II and III, who had undergone esophagectomy, were
obtained from the tumor bank of Charité Comprehensive CancerCenter (Charité Campus Buch, Berlin, Germany). Samples were
immediately snap-frozen in liquid nitrogen and stored at −80 °C.
Another independent validation cohort used for immunohistochemis-
try consisted of 36 formalin fixed and paraffin embedded (FFPE)
specimens. In total, 12 EAC, 12 BE and 12 NE were examined.
Patients' age ranged from 34 to 87 years, with a median age of 60 years.
We obtained tissue specimens from all subjects with informed written
consent approved by the local ethics committee of the Charité-Uni-
versitätsmedizin, Berlin. Each specimen included in this study was
histopathologically approved according to grade and stage (MV,
Institute of Pathology, University Hospital Bayreuth, Germany) using
standard International Federation of Gastrointestinal criteria.
Laser Capture Microdissection
Laser Capture Microdissection (LMD) was performed for all cases
except healthy tissue. Frozen specimens were serially sectioned in
5-μm slices with a cryostat and the first and last slide was stained with
hematoxylin and eosin to define the analyzed regions. After
transferring the 5 μm sections in between onto MMI membrane
slides, these were fixed in 70% isopropyl alcohol and then stained
with the MMI basic staining kit. LMD regions were defined by MV
(Institute of Pathology, Klinikum Bayreuth, Germany). For LMD a
Cellcut device equipped with a Nikon TE300 microscope (MMI AG,
Switzerland) was used for isolating desired cells from sections. Then
desired cells or areas were selected, cut and collected.
Microarray Analysis
Total RNA was extracted using the RNeasy Micro Kit (Qiagen)
according to the manufacturer's protocol. RNA quality was analyzed
by Bioanalyzer 2100 (Agilent). Only high quality RNA with RIN
above 7.0 was processed further. The Affymetrix Human Genome
U133plus 2.0 array (Affymetrix, Santa Clara, CA) was used for this
study. Preparation of labeled cRNA and hybridization were done
using the gene chip hybridization, wash, and stain kit (Affymetrix,
Santa Clara, CA), as described previously [11–13]. Two cycle labeling
was applied to all samples. Chip data quality was strictly controlled.
Besides the common quality control provided by gene chip operating
software, a scientific workflow for chip quality control was set up in
our lab including pseudo image plots, scatter MA plot and relative log
expression plot. Additionally, correlation analysis across gene chips
was also performed by Agilent GeneSpring software GX 10.2.
Data Analysis
Probe set data were generated with GeneChip Operation Software
(GCOS, Affymetrix). Raw data were further processed using tools
available from Bioconductor version 2.6 [14]. Background correction
and normalization were carried out using the Affymetrix package [15].
Results were filtered by the detection P-value, considering probes with
P-value b0.01 as ‘present’ and all others ‘absent’. Probes ‘present’ in at
least 50% of the samples of one group were examined for further
analysis. Differential expression with respect to control samples was
determined using the limma package in Bioconductor [16]. The False
Discovery Rate (FDR) was employed using Benjamini-Hochberg
procedure for multiple testing of the resulting P-value significance.
Principal component analysis (PCA) and unsupervised hierarchical
clustering were used to evaluate the relationships between patients'
groups. Gene annotations were based on Affymetrix Human Genome
U133 Plus 2.0 Array annotation data (hgu133plus2 package). Gene
Ontology enrichment was carried out using the DAVID Functional
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genes included in these microarrays and the normalized data have been
deposited in theGene ExpressionOmnibus database (http://www.ncbi.
nlm.nih.gov/geo/info/linking.html) under GEO accession number
GSE26886.
RNA Extraction and qRT-PCR
RNAextractions were carried out using the RNeasyMini Kit (Qiagen,
Valencia, CA). Total RNA quality and yield were assessed using a
bioanalyzer system (Agilent 2100 Bioanalyzer; Agilent Technologies,
Palo Alto, CA) and a spectrophotometer (NanoDrop ND-1000;
NanoDrop Technologies, Wilmington, DE). Only RNA with an
RNA integrity number N7.0 was used for RT-PCR analysis. For
quantification, the expression levels of genes found by microarray
analyses, RT-PCR was performed using pre-designed gene-specific
TaqMan probes and primer sets purchased from Applied Biosystems.
RT-PCR amplification was carried out using RNAUltraSense One-Step
Quantitative RT-PCR System (Invitrogen) on an ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems), according to the
manufacturer's instructions. All samples were amplified in triplicate
reactions. Gene expression was quantified relative to the expression of
internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
using Sequence Detector Software (SDS 2.2, Applied Biosystems) and
the relative quantificationmethod for quantitative RT-PCR. In addition,
GAPDH levels were also used to determine whether a given sample
contained sufficient mRNA to be included in the study. Samples for
which the Ct value for GAPDH above 22 were excluded from analysis.
The relative expression of each individual gene was calculated based on
the determined ΔCT values. The ΔCT value is the difference between
theCt value for an individual gene and the internal reference control gene
GAPDH [18]. ΔCT values correspond to a log-2 scale. The result of
quantitative gene expression was calculated as a 2−ΔCT relative to
GAPDH expression in the corresponding samples.
Immunohistochemistry
Immunohistochemistry was performed on 5 μm thin formalin
fixed paraffin sections using the biotin blocking system (Dako,
Glostrup, Denmark) and the ImmPRESS universal reagent (Vector
Laboratories Inc., Burlingame, CA). Primary antibody for CTHRC1
detection was mouse monoclonal anti-human CTHRC1 antibody
(Abcam ab72527, 1:1000). Primary antibody for INHBA detection
was rabbit polyclonal anti-human INHBA antibody (Sigma-Aldrich
Corporation, HPA020031, 1:200).Results and Discussion
Gene Expression Profiles of Samples are Consistent with
Histological Typing
Gene expression profiling using whole-human-genome microar-
rays (Affymetrix U133plus2) was performed on 21 EAC, 20 BE, 9
ESCC and 18 NE biopsies. By unsupervised hierarchical clustering
the tissue samples were separated into 4 distinct groups consistent
with their histological subtype. Clustering of the gene expression
profiles is depicted in the dendrogram (Figure 1). All 18 samples
taken from normal esophageal epithelium cluster together on the left
side group called CONTROL. Esophageal carcinoma samples belong
to the group in the middle, but they fall into two strictly separated
clusters. On the middle left, esophageal squamous cell carcinomas
(ESCC) cluster together, and on the middle right esophagealadenocarcinomas (EAC) are found. Samples taken from Barrett's
esophagus (BE) cluster together on the right side. Please note that for
each group all samples cluster together with not one mismatch.
Another approach, Principal component analysis (Supplement Figure 1)
demonstrated a similar grouping. The excellent agreement of gene
expression profiles with the histological subtypes might be a result of laser
capture microdissection, which is likely to be the superior approach in
terms of controlling tissue purity.
Several gene expression profiling studies of Barrett's esophagus and
esophageal carcinomas have been published to date, e.g., [19].
Cellular contamination within patient samples, or a mixture of tissue
types within a biopsy is a strong challenge for efforts to determine an
accurate cancer–related gene expression profile because gene
expression measurements can become skewed by this heterogeneity.
Here, we have applied laser microdissection (LMD) in order to get
access to almost “pure” samples of Barrett's epithelium, esophageal
adenocarcinoma or squamous carcinoma tissue. LMD enables the
isolation of specific cell populations from complex tissues under
morphological control, which is likely to be the superior approach in
terms of controlling tissue purity. In our study, LMD was applied not
only for all esophageal tumor samples, but also for BE samples
because BE biopsies often contain only few BE glands besides
squamous epithelium or stromal cells. LMD enabled us to obtain
purified columnar cells from each BE biopsy and use them as a source
for RNA extraction. Unsupervised hierarchical clustering and
principal component analysis of microarray data obtained distin-
guished samples into four distinct groups according to their
histopathology, demonstrating the quality of the LMD approach
and the microarray analysis.
Validation in an Independent Cohort
To verify our observed gene expression results, we investigated
expression levels of 12 randomly chosen genes with P b .01 by
real-time PCR and confirmed conclusively the microarray results
generated from the training cohort. Comparison of the obtained
fold-changes by array analysis versus real-time PCR confirmed our
approach as conservative, revealing higher expression differences in
the former (Supplement Table 2).
Examination of the Marker Expression on the Protein Level
CTHRC1 and INHBA antibodies detected a specific protein band
on western blots and thus were used for another validation of gene
expression results. Immunohistochemical analysis demonstrated
differential abundance of CTHRC1 and INHBA on the protein
level in paraffin tissue specimens of a third independent patient
cohort of 12 EAC, 5 intraepithelial neoplasia (IEN) specimens, and 7
BE from patients without tumor formation in the first five years after
biopsy sampling representing low risk BE, and 12 NE specimens.
Immunohistochemical staining showed that CTHRC1 was abundant
in 10 of 12 EAC specimens and in the 5 IEN specimens, but staining
was low in 7 BE specimens from patients without tumor formation.
In NE biopsies no CTHRC1 staining was detected. INHBA was
highly abundant in all EAC samples, highly abundant in the IEN
specimens, but staining was low in the BE samples and not detected at
all in NE specimens (Figure 2).
Analysis of Differentially Expressed Genes
The aim of this study was the generation of a database, which
allows the identification of genes or groups of genes with strong
Figure 1. Unsupervised hierarchical clustering of samples obtained from four different tissue types. Clustering of the gene expression
profiles of the 68 cases under study produced four main clusters. Depicted is a full-length view of the cluster dendrogram with cases
orientated along the horizontal axis. Hierarchical clustering analysis is called unsupervised if the relatedness of cases is determined only
by the similarity of their whole human genome expression profiles, independently of clinical or pathological parameters. Here, hierarchical
cluster analysis showed that the four tissues types are clearly distinct. All 18 samples taken from healthy esophageal epithelium (NE)
cluster together in the group on the left side. Carcinoma samples belong to the cluster group in the middle, encompassing two strictly
separated clusters of esophageal squamous cell carcinomas (ESCC) and of esophageal adenocarcinomas (EAC). Samples taken from
Barrett's esophagus (BE) form another cluster group on the right side. Please note that all samples of the different tissue types cluster
together with not one mismatch.
Translational Oncology Vol. 11, No. xx, 2018 Genome Wide Analysis of Barrett's Adenocarcinoma Dai et al. 119differential expression in esophageal carcinomas. To get an overview,
gene ontology analysis was used to determine significantly over- or
underrepresented biological processes, cellular components, and
molecular functions within the entire set of differentially expressed
genes. Entrez IDs were assigned to gene ontology categories accordingFigure 2. Immunohistochemical detection of CTHRC1 (A-D) and I
neoplasia and esophageal adenocarcinoma. Immunohistochemical d
formalin fixed paraffin sections. Cell nuclei were counterstained using
be found in healthy esophageal epithelium (A + E), low CTHRC1
adenocarcinomas, high CTHRC1 and INHBA expression was pred
expression of CTHRC1 / INHBA was observed in the intraepithelial
controls were obtained by omission of primary antibody (data not shto the annotations in the Affymetrix Human Genome U133 Plus 2.0
Array annotation data (hgu133plus2 package). Then these Entrez IDs
were subjected to DAVID functional annotation bioinformatics
microarray analysis, using the default feature listings and algorithm
settings, with the whole human genome as background. OntologyNHBA (E-H) expression in healthy epithelium, BE, intraepithelial
etection of CTHRC1 and INHBA (red) was performed on 5 μm thin
hematoxylin (blue). No specific CTHRC1 / INHBA expression could
/ INHBA expression was detected in Barrett's glands (B + F). In
ominantly observed in mucosa glands (D + H), moreover, high
neoplasia (C + G). Representative sections are shown. Negative
own). Pictures are 200× magnified.
Table 1. Peak Genes Up-Regulated in Esophageal Carcinomas
Gene Symbol Description Entrez BE logFC BE adj.P EAC logFC EAC adj.P ESCC logFC ESCC adj.P
BGN biglycan 633 0,18 5,56E−01 2,56 4,84E−13 2,70 6,16E-10
C11orf96 chromosome 11 open reading frame 96 387,763 2,12 3,20E−08 4,61 9,83E-21 3,76 2,93E-12
COCH coagulation factor C homolog, cochlin (Limulus polyphemus) 1690 0,76 1,03E-01 2,95 8,35E-09 2,77 1,33E-05
COL8A1 collagen, type VIII, alpha 1 1295 -0,67 1,45E-01 2,56 1,59E-07 2,72 1,23E-05
CTHRC1 collagen triple helix repeat containing 1 115,908 3,00 7,35E-10 5,31 1,50E-19 5,50 5,21E-15
FOXC1 forkhead box C1 2296 -1,35 2,50E-03 1,23 4,79E-03 2,57 1,68E-05
IL8 interleukin 8 3576 0,68 2,48E-01 2,73 6,77E-06 2,58 9,25E-04
INHBA inhibin, beta A 3624 0,33 3,88E-01 4,26 1,23E-17 5,13 8,01E-16
LEPREL4 leprecan-like 4 10,609 0,99 5,50E-04 3,03 6,17E-17 3,15 6,56E-13
MMP1 matrix metallopeptidase 1 (interstitial collagenase) 4312 2,51 3,07E-04 5,49 3,87E-12 7,12 6,53E-12
MTHFD1L methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like 25,902 0,30 3,51E-01 2,55 3,31E-12 2,94 2,54E-10
NNMT nicotinamide N-methyltransferase 4837 2,10 1,08E-05 4,18 4,33E-14 4,06 1,02E-09
PMEPA1 prostate transmembrane protein, androgen induced 1 56,937 1,27 7,58E-04 4,37 1,38E-18 3,94 4,07E-12
RGS1 regulator of G-protein signaling 1 5996 0,05 9,16E-01 2,89 3,07E-09 2,77 4,90E-06
SOCS3 suppressor of cytokine signaling 3 9021 1,02 1,70E-02 3,27 2,75E-11 3,89 5,91E-10
SPP1 secreted phosphoprotein 1 / osteopontin 6696 0,02 9,73E-01 2,89 1,26E-06 5,57 5,96E-11
SULF1 sulfatase 1 23,213 -0,16 7,48E-01 3,05 1,51E-08 3,13 4,29E-06
USP42 ubiquitin specific peptidase 42 84,132 0,02 9,23E-01 2,25 6,15E-18 2,91 2,70E-17
WDR72 WD repeat domain 72 256,764 1,93 7,52E-03 4,68 3,28E-09 5,76 1,97E-08
WISP1 WNT1 inducible signaling pathway protein 1 8840 0,17 6,57E-01 2,26 4,30E-08 3,10 1,48E-08
Depicted are genes whose expression is strongly up-regulated in esophageal carcinomas in comparison to NE. From left to right: Gene symbol and description; Entrez-ID; BE fold change, fold increase of gene
expression in BE vs. healthy samples; BE adjusted P-value; EAC fold change, fold increase of gene expression in esophageal adenocarcinoma vs. healthy samples; EAC adjusted P-value; ESCC fold change, fold
increase of gene expression in esophageal squamous carcinoma vs. healthy samples; ESCC adjusted P-value; Note that a log2-fold change is used. P-value, significance of this difference in gene expression.
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recorded (Suppl. Table 1).
This database can be queried in different ways - pursuing different
aims. In order to detect cancer-associated changes but to rule out
epithelium-specific changes, esophageal adenocarcinomas were
compared with their precursor tissue type, BE, and squamous
carcinomas were compared with healthy normal esophageal tissue,
NE. In an approach to identify the most consistently changed
individual genes, we searched for so-called peak genes with a fold
change N6-fold increase/decrease between any two tissue groups.
On the one hand, BE but also EAC and ESCC samples showed an
up-regulated representation of genes coding for proteins of the
extracellular environment (Table 1) such as MMP1, SPP1,
CTHRC1, INHBA and SULF1. Matrix metalloproteinases
(MMPs) are a family of zinc-dependent proteases that target the
degradation and proteolytic process of components of the extracel-
lular matrix [20]. An elevated expression of MMP1 in esophageal
cancers has been described [21]. Another gene, strongly up-regulated
in both types of esophageal carcinomas, Activin, the disulfide-linked
homodimer of inhibin-ßA (INHBA), is a ligand of the transforming
growth factor-beta (TGF-ß) superfamily. INHBA overexpression
promotes cell proliferation and may be epigenetically regulated in
esophageal adenocarcinoma [22]. Overexpression of activin A in
esophageal squamous cell carcinoma has been associated with
advanced nodal status, clinical stage, and a worse overall prognosis
[23]. Similarly, collagen triple helix repeat-containing 1 (CTHRC1)
is known to be aberrantly up-regulated in most human solid tumors
[24]. CTHRC1 drives cancer progression perhaps by increasing
cancer cell migration [25]. High levels of PMEPA1/TMEPAI
expression have been found in renal cell carcinoma, colon cancer,
breast cancer, and ovarian cancer as well as in several cancer cell lines
[26,27]. Genome-wide studies, which compared the gene expression
levels of invasive cancer tissues with normal counterpart tissues or
pre-invasive cancers, suggested that TMEPAI is one of the most
highly inducible genes in invasive cancers that converts TGF-β
signaling from a tumor suppressor to a tumor promoter [28]. These
lines of evidence suggest an oncogenic function of TMEPAI in manycancers. Genes strongly overexpressed in esophageal carcinomas
might be helpful for diagnosis and future therapeutic strategies.
On the other hand, genes belonging to the GO group epithelium
development were down-regulated in BE but also in EAC and ESCC
samples when compared to healthy esophageal epithelium. Interest-
ingly, many of the down-regulated peak genes in esophageal cancers
(Table 2) belong to the so-called epidermal differentiation complex
(EDC) [29]. Other genes strongly down-regulated in EAC and ESCC
such as CRTC1 and SCEL belong to the GO-group cornified
envelope of terminally differentiated keratinocytes. Expression of
these genes is necessary for differentiation frequently turned down in
carcinomas. For instance, CRNN, which was found to be
significantly down-regulated in esophageal carcinomas, is a
member of the EDC. The loss of CRNN expression correlates
with longer tumor length, deeper tumor invasion depth, more
advanced lymph node metastasis, and poorer survival [30]. Another
gene belonging to the EDC is S100A9, which was also strongly
down-regulated in both EAC and ESCC. In a proteomic approach,
S100A9 was found to be strongly down-regulated in ESCC [31].
Interestingly, also the transglutaminase 3, which is responsible for
crosslinking EDC matrix proteins was down-regulated. This means
that the formation of the epidermal layer is disturbed in the
carcinomas. Similarly SCEL, responsible for the assembly of
proteins in the cornified envelope was strongly down-regulated.
Recent results that SCEL is necessary for metastatic colorectal
cancer tumor growth in the liver [32].
Interestingly, also the expression of MAL (T-cell differentiation-
related gene) was significantly reduced in both EAC and ESCC
(Table 2). MAL promoter hypermethylation correlating with
decreased mRNA expression was reported [33] MAL is thought to
be a novel suppressor gene [34] with diagnostic value in colorectal and
esophageal cancers [35]. The protein has been localized to the
endoplasmic reticulum of T-cells and is a candidate linker protein in
T-cell signal transduction. The role of MAL for cancer immunity has
not been determined yet.
Retinol metabolism was also down-regulated in both types of
carcinomas, which is reflected by a strong loss of the expression of
Table 2. Peak Genes Down-Regulated in Esophageal Carcinomas
Gene Symbol Description Entrez BE logFC BE adj.P EAC logFC EAC adj.P ESCC logFC ESCC adj.P
ADH7 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide 131 −4,03 2,26E-13 −6,12 2,28E-21 −4,24 1,98E-10
CRNN Cornulin 49,860 −6,01 2,99E-12 −9,17 5,23E-20 −9,22 6,37E− 15
DHRS9 dehydrogenase/reductase (SDR family) member 9 10,170 -1,51 3,37E-03 −3,84 4,12E-11 −4,45 1,86E-09
DSC2 desmocollin 2 1824 −1,48 7,32E-04 −3,74 3,27E-13 −4,09 1,51E-10
DSG3 desmoglein 3 1830 −5,04 4,29E-13 −7,04 2,27E-19 −3,47 8,82E-06
EMP1 epithelial membrane protein 1 2012 −3,32 3,56E-09 −5,68 8,34E-18 −4,67 2,91E-10
FLG filaggrin 2312 −3,94 2,75E-09 −5,99 7,96E-16 −5,72 8,26E-11
GRHL3 grainyhead-like 3 (Drosophila) 57,822 −4,56 4,93E-17 −5,33 1,77E-20 −4,17 1,81E-11
IL1RN interleukin 1 receptor antagonist 3557 −2,47 4,32E-06 −5,51 5,58E-17 −5,20 1,64E-11
KRT13 keratin 13 3860 −6,47 1,69E-09 −10,04 1,72E-16 −6,59 6,13E-07
KRT4 keratin 4 3851 −5,36 1,36E-08 −8,57 1,16E-15 −8,22 9,77E-11
MAL mal, T-cell differentiation protein 4118 −4,30 2,94E-09 −8,95 1,01E-21 −9,01 2,42E− 16
MALL mal, T-cell differentiation protein-like 7851 -1,70 1,23E-03 −3,91 3,81E-11 −4,17 1,70E-08
S100A8 S100 calcium binding protein A8 6279 −5,18 1,97E-07 −8,87 5,95E-15 −3,98 1,11E-03
S100A9 S100 calcium binding protein A9 6280 −5,13 4,54E-10 −7,82 5,04E-17 −4,88 9,69E-07
SCEL sciellin 8796 −5,39 1,46E-11 −8,30 2,71E-19 −7,72 4,33E-13
SERPINB11 serpin peptidase inhibitor, clade B (ovalbumin), member 11 89,778 −2,69 8,06E-15 −3,03 2,51E-17 −2,89 5,76E-12
SERPINB13 serpin peptidase inhibitor, clade B (ovalbumin), member 13 5275 −6,23 5,27E-12 −8,59 9,12E-18 −5,04 1,51E-06
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 5055 −5,29 5,33E-13 −7,68 5,23E-20 −6,32 7,07E-12
SERPINB4 serpin peptidase inhibitor, clade B (ovalbumin), member 4 6318 −4,76 7,70E-08 −6,95 5,53E-13 −6,15 7,70E-08
SPINK7 serine peptidase inhibitor, Kazal type 7 (putative) 84,651 −4,18 8,83E-10 −7,40 2,24E-19 −7,23 6,51E-14
SPRR1A small proline-rich protein 1A 6698 −5,76 3,10E-08 −9,65 6,86E-16 −5,21 4,41E-05
SPRR1B small proline-rich protein 1B 6699 −5,34 3,36E-08 −8,60 3,64E-15 −3,78 1,19E-03
SPRR3 small proline-rich protein 3 6707 −5,33 2,19E-08 −9,49 3,09E-17 −8,46 6,13E-11
TGM3 transglutaminase 3 7053 −5,73 2,54E-14 −8,39 8,01E-22 −7,90 2,55E-15
Depicted are genes whose expression is strongly down-regulated in esophageal carcinomas in comparison to NE. From left to right: Gene symbol and description; Entrez-ID; BE fold change, fold decrease
of gene expression in BE vs. healthy samples; BE adjusted P-value; EAC fold change, fold decrease of gene expression in esophageal adenocarcinoma vs. healthy samples; EAC adjusted P-value; ESCC fold
change, fold decrease of gene expression in esophageal squamous carcinoma vs. healthy samples; ESCC adjusted P-value; Note that a log2-fold change is used. P-value, significance of this difference in gene
expression.
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member of the alcohol dehydrogenase family. However, it is
inefficient in ethanol oxidation, but active as a retinol dehydrogenase.
Since retinoic acid regulates the proliferation, differentiation, and
apoptosis of premalignant and malignant cells during carcinogenesis
[36], it is conceivable that a disturbance of its formation leads to
various disorders including malignancy. Moreover, we noted a
reduced activity in genes that are related to retinol metabolism
(UGT2B15, ADH7, ADH1C, DHRS9, CYP4B1) within EACADH7
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Table 3. Peak Genes Up-Regulated in BE and EAC
Gene Symbol Description Entrez BE logFC BE adj.P EAC logFC EAC adj.P
AGR2 anterior gradient 2 homolog (Xenopus laevis) 10,551 7,28 4,72E-19 6,40 4,29E-29
AGR3 anterior gradient 3 homolog (Xenopus laevis) 155,465 7,12 7,63E-24 5,44 7,67E-19
CENPV centromere protein V 201,161 4,68 1,61E-22 5,05 1,49E-24
CLRN3 clarin 3 119,467 5,02 1,31E-10 5,82 5,09E-13
CTSE cathepsin E 1510 7,35 1,37E-20 4,87 1,62E-13
GATA6 GATA binding protein 6 2627 7,21 2,07E-26 6,76 2,71E-25
GDA guanine deaminase 9615 4,67 4,08E-15 4,69 1,33E-15
GOLM1 golgi membrane protein 1 51,280 7,37 1,57E-35 6,01 1,83E-30
LGALS4 lectin, galactoside-binding, soluble, 4 3960 8,14 2,31E-37 7,16 4,47E-34
MUC13 mucin 13, cell surface associated 56,667 4,46 2,43E-16 4,88 1,92E-18
OLFM4 olfactomedin 4 10,562 6,74 2,10E-09 6,07 2,08E-08
PIGR polymeric immunoglobulin receptor 5284 8,49 2,89E-27 7,14 8,31E-24
PIP5K1B phosphatidylinositol-4-phosphate 5-kinase, type I, beta 8395 5,82 1,52E-25 5,13 3,55E-23
POSTN periostin, osteoblast specific factor 10,631 5,95 2,32E-22 5,17 6,02E-20
PROM1 prominin 1 8842 6,47 4,89E-26 6,02 8,39E-25
REG4 regenerating islet-derived family, member 4 83,998 6,75 7,04E-13 5,10 2,70E-09
RHPN2 rhophilin, Rho GTPase binding protein 2 85,415 4,83 2,76E-25 5,91 2,79E-30
SPINK1 serine peptidase inhibitor, Kazal type 1 6690 7,11 2,55E-21 6,55 4,01E-20
SULT1C2 sulfotransferase family, cytosolic, 1C, member 2 6819 8,03 8,34E-24 5,67 2,76E-17
TFF1 trefoil factor 1 7031 8,50 8,34E-24 5,53 8,74E-16
TMC5 transmembrane channel-like 5 79,838 6,42 2,15E-28 6,33 2,20E-28
TMPRSS3 transmembrane protease, serine 3 64,699 3,75 4,90E-13 4,72 2,51E-17
TOX3 TOX high mobility group box family member 3 27,324 6,64 1,42E-34 6,10 1,83E-32
TSPAN8 tetraspanin 8 7103 8,71 2,36E-43 7,91 6,74E-41
VCAN versican 1462 3,63 1,25E-14 4,63 1,59E-19
Depicted are the genes whose expression is strongly up-regulated in Barrett's esophagus (BE) as well as in esophageal adenocarcinoma (EAC) in comparison to NE. From left to right: Gene symbol and
description; Entrez-ID; BE fold change, fold increase of gene expression in BE vs. healthy samples; BE adjusted P-value; EAC fold change, fold increase of gene expression in esophageal adenocarcinoma vs.
healthy samples; EAC adjusted P-value; Note that a log2-fold change is used. P-value, significance of this difference in gene expression.
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genes such as GATA6, TOX3, PROM or are components of the cell
membrane. These genes could be helpful for early diagnosis of cancer in
Barrett tissues but their expression could also be increased due to the
replacement of the squamousmucosa by columnar epithelium in BE and
EAC. Therefore, the expression of the encoded proteins in gastrointes-
tinal carcinomas was checked using the protein atlas database [39]. For
instance, GREM1 (gremlin 1, DNA family BMP antagonist), ITLN1
(intelectin 1) and TM4SF4 (transmembrane 4 L six family member 4)
were significantly up-regulated in BE and EAC. Expression of these
genes was highly homogeneous in all samples of a given tissue and
therefore might be of particular value for early diagnosis. Interestingly,
the encoded proteins were detected in stomach carcinomas, but not in
the respective non-malignant tissues. Similarly, REG4 (Regenerating
islet-derived family, member 4) was significantly up-regulated in both
BE and even stronger in EAC (Table 3). Colorectal cancers along with
few stomach, pancreatic and ovarian cancers showed moderate to strong
cytoplasmic immunoreactivity for REG4. Aberrant expression of REG4
was associated with the growth, survival, adhesion and resistance to
apoptosis of tumor cells (e.g. [40]). Moreover, REG4 is considered a
novel prognostic factor in some gastroenterological carcinomas [41] and
was identified as a transcriptional target of GATA6 [42]. Patients
suffering from esophageal cancer with an amplification of GATA6 have a
poorer survival [43]. In our study, GATA6 was found to be significantly
up-regulated in both BE and EAC (Table 3).
Several researchers have investigated gene expression in Barrett's
esophagus. Greenawalt et al. [44] found that SOCS3, MMP3 and
MMP10 were up-regulated in ESCC and EAC, and that SERPINB2,
SEPINB3 and SPINK5were down-regulated in esophageal carcinomas,
which is in accordance with our data. Interestingly, they also searched
for genes up-regulated in BE and found an increased expression of
TFF1, LGALS4 and GATA6 (Table 3). Botelho et al. [45] searched for
gene expression using paraffin-embedded Barrett's esophagus tissuesamples. They also found down-regulation of ADH7 in esophageal
carcinomas and an up-regulation of TSPAN8 in BE (Tables 2,3).
Hyland et al. [46] performed gene expression analysis s of Barrett's
esophagus and matched normal mucosa. Ten of the top 50 genes in
their list of differentially expressed genes in BE vs. NE belong to the 25
peak genes depicted in Table 3. Warnecke-Eberz et al. [19] proposed a
diagnostic signature of 19 genes for esophageal carcinomas of both
subtypes that contained at least 3 genes of Table 1.
Recently, the Cancer Genome Atlas Research Network performed a
comprehensive molecular analysis of esophagus carcinomas derived from
Western and Eastern populations [47]. The previously detected
amplifications of GATA4 and GATA6 genes were confirmed.
Interestingly, an up-regulation of the p63 transcription network only in
ESCC was reported. Accordingly, we found an up-regulation of TP63 in
ESCC (0.67 log2fold vs. NE) in comparison to EAC (−5.6 log2fold) and
BE (−4.6 log2fold). However, we noted a down-regulation of the EDC
genes in esophageal carcinomas in comparison to NE (Table 2). EDC
genes are thought to be target genes of p63 [44].
In summary, a database of gene expression in BE and esophageal
carcinomas was generated which can be queried in different ways, e.g. in
order to find carcinoma-associated markers with differential expression
in both esophageal squamous cell carcinomas and adenocarcinomas.
Another aim is to identify a subset of markers that may allow detecting
patients at risk for esophageal adenocarcinoma at a preneoplastic stage.
Of course, there are many other kinds of possible queries, e.g. related to
networks of genes, which are affected by the changes in differentiation
during cancer development. The examples given here are intended to
show that by using this database genes or groups of related genes can be
identified which might be helpful for early diagnosis of esophageal
carcinomas or for treatment and monitoring of this disease. The next
step is to kick off a retrospective study with more patients and long
follow-up in order to evaluate the changes in gene expression identified
in our experimental approach.
Translational Oncology Vol. 11, No. xx, 2018 Genome Wide Analysis of Barrett's Adenocarcinoma Dai et al. 123Conclusions
Our study provides high quality data, e.g. in order to determine a
subset of markers for the identification of patients at risk for
esophageal adenocarcinoma at a preneoplastic stage or markers which
may lead to a better disease management.
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